Alexandra V. Vylegzhanina,Ivan A. Bespalov,Ksenia A. Novototskaya-Vlasova,Brandon M. Hall,Anatoli S. Gleiberman,Han Yu,Olga V. Leontieva,Katerina I. Leonova,Oleg V. Kurnasov,Andrei L. Osterman,Grace K. Dy,Alexey A. Komissarov,Elena Vasilieva,Jeff Gehlhausen,Akiko Iwasaki,Christine B. Ambrosone,Takemasa Tsuji,Junko Matsuzaki,Kunle Odunsi,Ekaterina L. Andrianova
出处
期刊:Cancer research communications日期:2023-10-23卷期号:3 (11): 2256-2267被引量:3
Long interspersed nuclear element-1 (LINE-1 or L1), the most abundant family of autonomous retrotransposons occupying over 17% of human DNA, is epigenetically silenced in normal tissues by the mechanisms involving p53 but is frequently derepressed in cancer, suggesting that L1-encoded proteins may act as tumor-associated antigens recognized by the immune system. In this study, we established an immunoassay to detect circulating autoantibodies against L1 proteins in human blood. Using this assay in >2,800 individuals with or without cancer, we observed significantly higher IgG titers against L1-encoded ORF1p and ORF2p in patients with lung, pancreatic, ovarian, esophageal, and liver cancers than in healthy individuals. Remarkably, elevated levels of anti-ORF1p-reactive IgG were observed in patients with cancer with disease stages 1 and 2, indicating that the immune response to L1 antigens can occur in the early phases of carcinogenesis. We concluded that the antibody response against L1 antigens could contribute to the diagnosis and determination of immunoreactivity of tumors among cancer types that frequently escape early detection.